|
UVRAG expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.99280649946377E-15 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
3.433800E-01 |
| Stage1-vs-Stage3 |
7.823600E-02 |
| Stage1-vs-Stage4 |
2.143200E-03 |
| Stage2-vs-Stage3 |
6.251000E-01 |
| Stage2-vs-Stage4 |
7.787900E-02 |
| Stage3-vs-Stage4 |
1.687190E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.75019998494008E-10 |
| Normal-vs-Asian |
1.66588964845005E-12 |
| Caucasian-vs-AfricanAmerican |
8.080200E-01 |
| Caucasian-vs-Asian |
5.844600E-01 |
| AfricanAmerican-vs-Asian |
5.596400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.507800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
4.15409999998673E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.351800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.025900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.003200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.383000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.382800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.117000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.757800E-01 |
| Classical-VS-Follicular |
9.492600E-01 |
| Classical-VS-Other |
6.211400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.525800E-01 |
| Tall-VS-Other |
9.845800E-01 |
| Tall-VS-Normal |
2.44540054872289E-10 |
| Follicular-VS-Other |
6.338800E-01 |
| Follicular-VS-Normal |
1.62481139653892E-12 |
| Other-VS-Normal |
3.58870000000122E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.11022302462516E-15 |
| N0-vs-N1 |
3.408800E-01 |
|
|
